A genetically targeted enzyme replacement therapy for advanced heart failure.

Repair of thisJournal of Cardiac Failure Publishes Results From Celladon Corporation first-in – human phase 1/2 study in advanced heart failureCelladon Corporation announced the publication of results from a Phase 1/2 trial with MYDICAR , a genetically targeted enzyme replacement therapy for advanced heart failure, in the April 2009 issue of the Journal of Cardiac Failure. The CUPID clinical trial has demonstrated acceptable safety profile and produced quantitative evidence of biological activity in a number of important parameters for the assessment of heart failure.

– This peer reviewed publication of our results further confirmed our goal and approach, and we are pleased continued ability of MYDICAR evaluate the cardiac function in more patients in the Phase 2 portion of the study to improve, said Krisztina M. Chief Executive Officer of Celladon.. The results of this study are data from the Phase 1 portion of this ongoing Phase 1/2 study for Cohorts 1 and 2 at 12 months follow-up and cohort 3 of 6 months follow-up.A preliminary evaluation of this technique, that researchers generated KBM2L list specific non-Hodgkin’s lymphoma of the stomach in that one of its authors, each graduate computer scientist and information interprets Doctors. Computing Institute, KBM2L lists can be be imposed on other diseases.